Meeting
2015 ASCO Annual Meeting
A phase Ib/II trial with expansion of patients at the MTD trial of olaparib plus weekly (metronomic) carboplatin and paclitaxel in relapsed ovarian cancer patients.
Authors
Saul E. Rivkin
Swedish Cancer Inst, Seattle, WA
Saul E. Rivkin , Desiree Iriarte , Heather Sloan , Cara Wiseman , James Moon , Gary E. Goodman , Amy Bondurant , Daniel Veljovich , Peter Y. Z. Jiang , Tanya A. Wahl , Chirag Shah , Charles Drescher , Henry G. Kaplan , William A. Peters , Erin Ellis , Mehmet F. Fer , Min S. Park , Eileen Johnston
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT01650376
Citation
J Clin Oncol 33, 2015 (suppl; abstr 5573)
DOI
10.1200/jco.2015.33.15_suppl.5573
Abstract #
5573
Poster Bd #
131
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Phase Ib/II with expansion of patients at the MTD study of olaparib plus weekly (metronomic) carboplatin and paclitaxel in relapsed ovarian cancer patients.
First Author: Saul E. Rivkin
Poster
2022 ASCO Annual Meeting
A randomized phase II trial of mirvetuximab soravtansine (IMGN853), in folate receptor alpha (FRα)-high recurrent ovarian cancer eligible for platinum-based chemotherapy.
First Author: Fabian Trillsch
Poster
2013 ASCO Annual Meeting
A phase I/II study of the vascular disrupting agent BNC105P in combination with gemcitabine-carboplatin in partially platinum-sensitive ovarian cancer patients in first or second relapse: An international collaborative group trial of ANZGOG and HOG.
First Author: Danny Rischin
Poster
2012 ASCO Annual Meeting
Phase II trial of irinotecan plus bevacizumab for heavily pretreated recurrent ovarian cancer.
First Author: Salvia Sanjay Jain